Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
VVV default model Dolphin token market cap surges, POD hits a new high above 170 million dollars

VVV default model Dolphin token market cap surges, POD hits a new high above 170 million dollars

ChaincatcherChaincatcher2026/05/11 02:54
Show original

According to ChainCatcher, monitoring by GMGN shows that the Base ecosystem token POD (dphn.ai) saw a sharp increase in market capitalization this morning, briefly surpassing 170 million US dollars and currently at 130 million US dollars, with the 24-hour gain narrowing to 82%. During the same period, trading volume reached 6.3 million US dollars.

dphn.ai is an AI model development and DePIN project, providing the "Dolphin Mistral 24B Venice Edition" — the default uncensored AI model on the Venice platform. Previously, during a significant rise in VVV, POD also surged as a core model provider. This increase may be further influenced by a retweet from Base co-founder Jesse, with related sentiment continuing to ferment.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56